Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis.

Authors:
Lin C; Li ZL; Cai XL; Hu SY; Lv F and 2 more

Journal:
World J Diabetes

Publication Year: 2023

DOI:
10.4239/wjd.v14.i10.1573

PMCID:
PMC10642417

PMID:
37970134

Journal Information

Full Title: World J Diabetes

Abbreviation: World J Diabetes

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology & Metabolism

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict-of-interest statement: LJ has received fees for lecture presentations and for consulting from AstraZeneca, Merck, Metabasis, MSD, Novartis, Eli Lilly, Roche, Sanofi-Aventis and Takeda. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare. No other support from any organization for the submitted work other than that described above."

Evidence found in paper:

"Supported by Beijing Natural Science Foundation, No. 7202216; National Natural Science Foundation of China, No. 81970698 and No. 81970708."

Evidence found in paper:

"This systematic review and indirect meta-analysis was conducted in line with the criteria of Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) protocol[]. Registration has been accomplished on International Prospective Register of Systematic Reviews (PROSPERO) platform as CRD42022334206."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025